Search results
Always Tired in the Afternoon? Here Are 13 Possible Reasons for Your Fatigue
Parade via Yahoo News· 3 hours agoSources Max Kerr DDS, D-ABDSM, dental sleep expert with Sleep Better Austin Dr. Ilene Ruhoy, MD & ...
American College of Surgeons Commends U.S. Surgeon | Newswise
Newswise· 14 hours ago“Firearm violence has been a public health crisis in the United States for many years now, and we are pleased to see that the Surgeon General is addressing it in this Advisory, laying out the ...
50 Funny Tweets From June That Had Me Laughing Uncontrollably Throughout The Entire Month
BuzzFeed via Yahoo News· 2 hours agoThey delivered 70 boxes of snacks and water for our summer program. I unloaded 3 hand trucks in like...
Honing Catheter Ablation Techniques for Atrial Fibrillation
Medscape· 2 days ago...Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation (REAL-AF)...
The Swiftly Evolving Story of EGFR-Mutated NSCLC Management
MedPage Today· 4 days ago"Understanding mechanisms of resistance may enable the personalization of sequential...
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach...
Morningstar· 5 days agoPALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western
Osteoarthritis Drugs Need Trials With Appropriate Endpoints
Medscape· 5 days agoFor the elusive target of disease-modifying OA drugs (DMOADs), "there have been a lot of...
Cellular Fountain of Youth: New T-Cell Discovery Rewrites the Rules of Aging
SciTechDaily· 7 days agoResearchers at St. Jude Children’s Research Hospital and the University of Minnesota have discovered...
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for...
Morningstar· 5 days agoGilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV ...
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2D
MedPage Today· 3 days agoAfter 36 weeks of treatment with retatrutide, people with type 2 diabetes on most doses had...